
Radiopharmaceuticals for Diagnosis Industry Research Report 2025
Description
Summary
According to APO Research, the global Radiopharmaceuticals for Diagnosis market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Radiopharmaceuticals for Diagnosis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Radiopharmaceuticals for Diagnosis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Radiopharmaceuticals for Diagnosis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Radiopharmaceuticals for Diagnosis include Atom High-tech Co., Ltd., Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd. Jiangyuan Pharmaceutical Factory, Tianjin Said Biopharmaceutical Co., Ltd., Shenzhen Larven Bioengineering Technology Co., Ltd., Shanghai Atom Kexing Pharmaceutical Co., Ltd., Shanghai Xinke Pharmaceutical Co., Ltd., Ningbo Jun'an Pharmaceutical Technology Co., Ltd., Guangzhou Atom High-tech Isotope Pharmaceutical Co., Ltd. and Guangdong Xi'ai Pharmaceutical Co., Ltd., etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Radiopharmaceuticals for Diagnosis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Radiopharmaceuticals for Diagnosis.
The report will help the Radiopharmaceuticals for Diagnosis manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Radiopharmaceuticals for Diagnosis market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Radiopharmaceuticals for Diagnosis market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Radiopharmaceuticals for Diagnosis Segment by Company
Atom High-tech Co., Ltd.
Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd. Jiangyuan Pharmaceutical Factory
Tianjin Said Biopharmaceutical Co., Ltd.
Shenzhen Larven Bioengineering Technology Co., Ltd.
Shanghai Atom Kexing Pharmaceutical Co., Ltd.
Shanghai Xinke Pharmaceutical Co., Ltd.
Ningbo Jun'an Pharmaceutical Technology Co., Ltd.
Guangzhou Atom High-tech Isotope Pharmaceutical Co., Ltd.
Guangdong Xi'ai Pharmaceutical Co., Ltd.
Chengdu Zhonghe Gaotong Isotope Co., Ltd.
Chengdu Yunke Pharmaceutical Co., Ltd.
Chengdu Xinke Pharmaceutical Co., Ltd.
Beijing Zhibo High-tech Biotechnology Co., Ltd.
RadioMedix, Inc.
PDRadiopharma Inc.
Lantheus
Jubilant Radiopharma
GE Healthcare Ltd
DOE IP
Radiopharmaceuticals for Diagnosis Segment by Type
Strontium [89Sr] Chloride
Sodium Iodide [131I]
Iodine [125I] Sealed Seed Source
Technetium [99mTc] Pentetate
Technetium [99mTc] Polymerized Albumin
Technetium [99mTc] Dithiodithiocarbamate
Other
Radiopharmaceuticals for Diagnosis Segment by Application
Hospital
Clinic
Other
Radiopharmaceuticals for Diagnosis Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Radiopharmaceuticals for Diagnosis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Radiopharmaceuticals for Diagnosis and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Radiopharmaceuticals for Diagnosis.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Radiopharmaceuticals for Diagnosis manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Radiopharmaceuticals for Diagnosis by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Radiopharmaceuticals for Diagnosis in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, the global Radiopharmaceuticals for Diagnosis market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Radiopharmaceuticals for Diagnosis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Radiopharmaceuticals for Diagnosis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Radiopharmaceuticals for Diagnosis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Radiopharmaceuticals for Diagnosis include Atom High-tech Co., Ltd., Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd. Jiangyuan Pharmaceutical Factory, Tianjin Said Biopharmaceutical Co., Ltd., Shenzhen Larven Bioengineering Technology Co., Ltd., Shanghai Atom Kexing Pharmaceutical Co., Ltd., Shanghai Xinke Pharmaceutical Co., Ltd., Ningbo Jun'an Pharmaceutical Technology Co., Ltd., Guangzhou Atom High-tech Isotope Pharmaceutical Co., Ltd. and Guangdong Xi'ai Pharmaceutical Co., Ltd., etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Radiopharmaceuticals for Diagnosis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Radiopharmaceuticals for Diagnosis.
The report will help the Radiopharmaceuticals for Diagnosis manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Radiopharmaceuticals for Diagnosis market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Radiopharmaceuticals for Diagnosis market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Radiopharmaceuticals for Diagnosis Segment by Company
Atom High-tech Co., Ltd.
Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd. Jiangyuan Pharmaceutical Factory
Tianjin Said Biopharmaceutical Co., Ltd.
Shenzhen Larven Bioengineering Technology Co., Ltd.
Shanghai Atom Kexing Pharmaceutical Co., Ltd.
Shanghai Xinke Pharmaceutical Co., Ltd.
Ningbo Jun'an Pharmaceutical Technology Co., Ltd.
Guangzhou Atom High-tech Isotope Pharmaceutical Co., Ltd.
Guangdong Xi'ai Pharmaceutical Co., Ltd.
Chengdu Zhonghe Gaotong Isotope Co., Ltd.
Chengdu Yunke Pharmaceutical Co., Ltd.
Chengdu Xinke Pharmaceutical Co., Ltd.
Beijing Zhibo High-tech Biotechnology Co., Ltd.
RadioMedix, Inc.
PDRadiopharma Inc.
Lantheus
Jubilant Radiopharma
GE Healthcare Ltd
DOE IP
Radiopharmaceuticals for Diagnosis Segment by Type
Strontium [89Sr] Chloride
Sodium Iodide [131I]
Iodine [125I] Sealed Seed Source
Technetium [99mTc] Pentetate
Technetium [99mTc] Polymerized Albumin
Technetium [99mTc] Dithiodithiocarbamate
Other
Radiopharmaceuticals for Diagnosis Segment by Application
Hospital
Clinic
Other
Radiopharmaceuticals for Diagnosis Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Radiopharmaceuticals for Diagnosis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Radiopharmaceuticals for Diagnosis and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Radiopharmaceuticals for Diagnosis.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Radiopharmaceuticals for Diagnosis manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Radiopharmaceuticals for Diagnosis by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Radiopharmaceuticals for Diagnosis in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
131 Pages
- 1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
- 2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Radiopharmaceuticals for Diagnosis Market Size (2020-2031)
- 2.2.2 Global Radiopharmaceuticals for Diagnosis Sales (2020-2031)
- 2.2.3 Global Radiopharmaceuticals for Diagnosis Market Average Price (2020-2031)
- 2.3 Radiopharmaceuticals for Diagnosis by Type
- 2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- 2.3.2 Strontium [89Sr] Chloride
- 2.3.3 Sodium Iodide [131I]
- 2.3.4 Iodine [125I] Sealed Seed Source
- 2.3.5 Technetium [99mTc] Pentetate
- 2.3.6 Technetium [99mTc] Polymerized Albumin
- 2.3.7 Technetium [99mTc] Dithiodithiocarbamate
- 2.3.8 Other
- 2.4 Radiopharmaceuticals for Diagnosis by Application
- 2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Other
- 3 Market Competitive Landscape by Manufacturers
- 3.1 Global Radiopharmaceuticals for Diagnosis Market Competitive Situation by Manufacturers (2020 Versus 2024)
- 3.2 Global Radiopharmaceuticals for Diagnosis Sales (K Units) of Manufacturers (2020-2025)
- 3.3 Global Radiopharmaceuticals for Diagnosis Revenue of Manufacturers (2020-2025)
- 3.4 Global Radiopharmaceuticals for Diagnosis Average Price by Manufacturers (2020-2025)
- 3.5 Global Radiopharmaceuticals for Diagnosis Industry Ranking, 2023 VS 2024 VS 2025
- 3.6 Global Manufacturers of Radiopharmaceuticals for Diagnosis, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Radiopharmaceuticals for Diagnosis, Product Type & Application
- 3.8 Global Manufacturers of Radiopharmaceuticals for Diagnosis, Established Date
- 3.9 Global Radiopharmaceuticals for Diagnosis Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
- 4 Manufacturers Profiled
- 4.1 Atom High-tech Co., Ltd.
- 4.1.1 Atom High-tech Co., Ltd. Company Information
- 4.1.2 Atom High-tech Co., Ltd. Business Overview
- 4.1.3 Atom High-tech Co., Ltd. Radiopharmaceuticals for Diagnosis Sales, Revenue and Gross Margin (2020-2025)
- 4.1.4 Atom High-tech Co., Ltd. Radiopharmaceuticals for Diagnosis Product Portfolio
- 4.1.5 Atom High-tech Co., Ltd. Recent Developments
- 4.2 Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd. Jiangyuan Pharmaceutical Factory
- 4.2.1 Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd. Jiangyuan Pharmaceutical Factory Company Information
- 4.2.2 Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd. Jiangyuan Pharmaceutical Factory Business Overview
- 4.2.3 Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd. Jiangyuan Pharmaceutical Factory Radiopharmaceuticals for Diagnosis Sales, Revenue and Gross Margin (2020-2025)
- 4.2.4 Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd. Jiangyuan Pharmaceutical Factory Radiopharmaceuticals for Diagnosis Product Portfolio
- 4.2.5 Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd. Jiangyuan Pharmaceutical Factory Recent Developments
- 4.3 Tianjin Said Biopharmaceutical Co., Ltd.
- 4.3.1 Tianjin Said Biopharmaceutical Co., Ltd. Company Information
- 4.3.2 Tianjin Said Biopharmaceutical Co., Ltd. Business Overview
- 4.3.3 Tianjin Said Biopharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Sales, Revenue and Gross Margin (2020-2025)
- 4.3.4 Tianjin Said Biopharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Product Portfolio
- 4.3.5 Tianjin Said Biopharmaceutical Co., Ltd. Recent Developments
- 4.4 Shenzhen Larven Bioengineering Technology Co., Ltd.
- 4.4.1 Shenzhen Larven Bioengineering Technology Co., Ltd. Company Information
- 4.4.2 Shenzhen Larven Bioengineering Technology Co., Ltd. Business Overview
- 4.4.3 Shenzhen Larven Bioengineering Technology Co., Ltd. Radiopharmaceuticals for Diagnosis Sales, Revenue and Gross Margin (2020-2025)
- 4.4.4 Shenzhen Larven Bioengineering Technology Co., Ltd. Radiopharmaceuticals for Diagnosis Product Portfolio
- 4.4.5 Shenzhen Larven Bioengineering Technology Co., Ltd. Recent Developments
- 4.5 Shanghai Atom Kexing Pharmaceutical Co., Ltd.
- 4.5.1 Shanghai Atom Kexing Pharmaceutical Co., Ltd. Company Information
- 4.5.2 Shanghai Atom Kexing Pharmaceutical Co., Ltd. Business Overview
- 4.5.3 Shanghai Atom Kexing Pharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Sales, Revenue and Gross Margin (2020-2025)
- 4.5.4 Shanghai Atom Kexing Pharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Product Portfolio
- 4.5.5 Shanghai Atom Kexing Pharmaceutical Co., Ltd. Recent Developments
- 4.6 Shanghai Xinke Pharmaceutical Co., Ltd.
- 4.6.1 Shanghai Xinke Pharmaceutical Co., Ltd. Company Information
- 4.6.2 Shanghai Xinke Pharmaceutical Co., Ltd. Business Overview
- 4.6.3 Shanghai Xinke Pharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Sales, Revenue and Gross Margin (2020-2025)
- 4.6.4 Shanghai Xinke Pharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Product Portfolio
- 4.6.5 Shanghai Xinke Pharmaceutical Co., Ltd. Recent Developments
- 4.7 Ningbo Jun'an Pharmaceutical Technology Co., Ltd.
- 4.7.1 Ningbo Jun'an Pharmaceutical Technology Co., Ltd. Company Information
- 4.7.2 Ningbo Jun'an Pharmaceutical Technology Co., Ltd. Business Overview
- 4.7.3 Ningbo Jun'an Pharmaceutical Technology Co., Ltd. Radiopharmaceuticals for Diagnosis Sales, Revenue and Gross Margin (2020-2025)
- 4.7.4 Ningbo Jun'an Pharmaceutical Technology Co., Ltd. Radiopharmaceuticals for Diagnosis Product Portfolio
- 4.7.5 Ningbo Jun'an Pharmaceutical Technology Co., Ltd. Recent Developments
- 4.8 Guangzhou Atom High-tech Isotope Pharmaceutical Co., Ltd.
- 4.8.1 Guangzhou Atom High-tech Isotope Pharmaceutical Co., Ltd. Company Information
- 4.8.2 Guangzhou Atom High-tech Isotope Pharmaceutical Co., Ltd. Business Overview
- 4.8.3 Guangzhou Atom High-tech Isotope Pharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Sales, Revenue and Gross Margin (2020-2025)
- 4.8.4 Guangzhou Atom High-tech Isotope Pharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Product Portfolio
- 4.8.5 Guangzhou Atom High-tech Isotope Pharmaceutical Co., Ltd. Recent Developments
- 4.9 Guangdong Xi'ai Pharmaceutical Co., Ltd.
- 4.9.1 Guangdong Xi'ai Pharmaceutical Co., Ltd. Company Information
- 4.9.2 Guangdong Xi'ai Pharmaceutical Co., Ltd. Business Overview
- 4.9.3 Guangdong Xi'ai Pharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Sales, Revenue and Gross Margin (2020-2025)
- 4.9.4 Guangdong Xi'ai Pharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Product Portfolio
- 4.9.5 Guangdong Xi'ai Pharmaceutical Co., Ltd. Recent Developments
- 4.10 Chengdu Zhonghe Gaotong Isotope Co., Ltd.
- 4.10.1 Chengdu Zhonghe Gaotong Isotope Co., Ltd. Company Information
- 4.10.2 Chengdu Zhonghe Gaotong Isotope Co., Ltd. Business Overview
- 4.10.3 Chengdu Zhonghe Gaotong Isotope Co., Ltd. Radiopharmaceuticals for Diagnosis Sales, Revenue and Gross Margin (2020-2025)
- 4.10.4 Chengdu Zhonghe Gaotong Isotope Co., Ltd. Radiopharmaceuticals for Diagnosis Product Portfolio
- 4.10.5 Chengdu Zhonghe Gaotong Isotope Co., Ltd. Recent Developments
- 4.11 Chengdu Yunke Pharmaceutical Co., Ltd.
- 4.11.1 Chengdu Yunke Pharmaceutical Co., Ltd. Company Information
- 4.11.2 Chengdu Yunke Pharmaceutical Co., Ltd. Business Overview
- 4.11.3 Chengdu Yunke Pharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Sales, Revenue and Gross Margin (2020-2025)
- 4.11.4 Chengdu Yunke Pharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Product Portfolio
- 4.11.5 Chengdu Yunke Pharmaceutical Co., Ltd. Recent Developments
- 4.12 Chengdu Xinke Pharmaceutical Co., Ltd.
- 4.12.1 Chengdu Xinke Pharmaceutical Co., Ltd. Company Information
- 4.12.2 Chengdu Xinke Pharmaceutical Co., Ltd. Business Overview
- 4.12.3 Chengdu Xinke Pharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Sales, Revenue and Gross Margin (2020-2025)
- 4.12.4 Chengdu Xinke Pharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Product Portfolio
- 4.12.5 Chengdu Xinke Pharmaceutical Co., Ltd. Recent Developments
- 4.13 Beijing Zhibo High-tech Biotechnology Co., Ltd.
- 4.13.1 Beijing Zhibo High-tech Biotechnology Co., Ltd. Company Information
- 4.13.2 Beijing Zhibo High-tech Biotechnology Co., Ltd. Business Overview
- 4.13.3 Beijing Zhibo High-tech Biotechnology Co., Ltd. Radiopharmaceuticals for Diagnosis Sales, Revenue and Gross Margin (2020-2025)
- 4.13.4 Beijing Zhibo High-tech Biotechnology Co., Ltd. Radiopharmaceuticals for Diagnosis Product Portfolio
- 4.13.5 Beijing Zhibo High-tech Biotechnology Co., Ltd. Recent Developments
- 4.14 RadioMedix, Inc.
- 4.14.1 RadioMedix, Inc. Company Information
- 4.14.2 RadioMedix, Inc. Business Overview
- 4.14.3 RadioMedix, Inc. Radiopharmaceuticals for Diagnosis Sales, Revenue and Gross Margin (2020-2025)
- 4.14.4 RadioMedix, Inc. Radiopharmaceuticals for Diagnosis Product Portfolio
- 4.14.5 RadioMedix, Inc. Recent Developments
- 4.15 PDRadiopharma Inc.
- 4.15.1 PDRadiopharma Inc. Company Information
- 4.15.2 PDRadiopharma Inc. Business Overview
- 4.15.3 PDRadiopharma Inc. Radiopharmaceuticals for Diagnosis Sales, Revenue and Gross Margin (2020-2025)
- 4.15.4 PDRadiopharma Inc. Radiopharmaceuticals for Diagnosis Product Portfolio
- 4.15.5 PDRadiopharma Inc. Recent Developments
- 4.16 Lantheus
- 4.16.1 Lantheus Company Information
- 4.16.2 Lantheus Business Overview
- 4.16.3 Lantheus Radiopharmaceuticals for Diagnosis Sales, Revenue and Gross Margin (2020-2025)
- 4.16.4 Lantheus Radiopharmaceuticals for Diagnosis Product Portfolio
- 4.16.5 Lantheus Recent Developments
- 4.17 Jubilant Radiopharma
- 4.17.1 Jubilant Radiopharma Company Information
- 4.17.2 Jubilant Radiopharma Business Overview
- 4.17.3 Jubilant Radiopharma Radiopharmaceuticals for Diagnosis Sales, Revenue and Gross Margin (2020-2025)
- 4.17.4 Jubilant Radiopharma Radiopharmaceuticals for Diagnosis Product Portfolio
- 4.17.5 Jubilant Radiopharma Recent Developments
- 4.18 GE Healthcare Ltd
- 4.18.1 GE Healthcare Ltd Company Information
- 4.18.2 GE Healthcare Ltd Business Overview
- 4.18.3 GE Healthcare Ltd Radiopharmaceuticals for Diagnosis Sales, Revenue and Gross Margin (2020-2025)
- 4.18.4 GE Healthcare Ltd Radiopharmaceuticals for Diagnosis Product Portfolio
- 4.18.5 GE Healthcare Ltd Recent Developments
- 4.19 DOE IP
- 4.19.1 DOE IP Company Information
- 4.19.2 DOE IP Business Overview
- 4.19.3 DOE IP Radiopharmaceuticals for Diagnosis Sales, Revenue and Gross Margin (2020-2025)
- 4.19.4 DOE IP Radiopharmaceuticals for Diagnosis Product Portfolio
- 4.19.5 DOE IP Recent Developments
- 5 Global Radiopharmaceuticals for Diagnosis Market Scenario by Region
- 5.1 Global Radiopharmaceuticals for Diagnosis Market Size by Region: 2020 VS 2024 VS 2031
- 5.2 Global Radiopharmaceuticals for Diagnosis Sales by Region: 2020-2031
- 5.2.1 Global Radiopharmaceuticals for Diagnosis Sales by Region: 2020-2025
- 5.2.2 Global Radiopharmaceuticals for Diagnosis Sales by Region: 2026-2031
- 5.3 Global Radiopharmaceuticals for Diagnosis Revenue by Region: 2020-2031
- 5.3.1 Global Radiopharmaceuticals for Diagnosis Revenue by Region: 2020-2025
- 5.3.2 Global Radiopharmaceuticals for Diagnosis Revenue by Region: 2026-2031
- 5.4 North America Radiopharmaceuticals for Diagnosis Market Facts & Figures by Country
- 5.4.1 North America Radiopharmaceuticals for Diagnosis Market Size by Country: 2020 VS 2024 VS 2031
- 5.4.2 North America Radiopharmaceuticals for Diagnosis Sales by Country (2020-2031)
- 5.4.3 North America Radiopharmaceuticals for Diagnosis Revenue by Country (2020-2031)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Radiopharmaceuticals for Diagnosis Market Facts & Figures by Country
- 5.5.1 Europe Radiopharmaceuticals for Diagnosis Market Size by Country: 2020 VS 2024 VS 2031
- 5.5.2 Europe Radiopharmaceuticals for Diagnosis Sales by Country (2020-2031)
- 5.5.3 Europe Radiopharmaceuticals for Diagnosis Revenue by Country (2020-2031)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Radiopharmaceuticals for Diagnosis Market Facts & Figures by Country
- 5.6.1 Asia Pacific Radiopharmaceuticals for Diagnosis Market Size by Country: 2020 VS 2024 VS 2031
- 5.6.2 Asia Pacific Radiopharmaceuticals for Diagnosis Sales by Country (2020-2031)
- 5.6.3 Asia Pacific Radiopharmaceuticals for Diagnosis Revenue by Country (2020-2031)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Radiopharmaceuticals for Diagnosis Market Facts & Figures by Country
- 5.7.1 South America Radiopharmaceuticals for Diagnosis Market Size by Country: 2020 VS 2024 VS 2031
- 5.7.2 South America Radiopharmaceuticals for Diagnosis Sales by Country (2020-2031)
- 5.7.3 South America Radiopharmaceuticals for Diagnosis Revenue by Country (2020-2031)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Radiopharmaceuticals for Diagnosis Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Radiopharmaceuticals for Diagnosis Market Size by Country: 2020 VS 2024 VS 2031
- 5.8.2 Middle East and Africa Radiopharmaceuticals for Diagnosis Sales by Country (2020-2031)
- 5.8.3 Middle East and Africa Radiopharmaceuticals for Diagnosis Revenue by Country (2020-2031)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
- 6 Segment by Type
- 6.1 Global Radiopharmaceuticals for Diagnosis Sales by Type (2020-2031)
- 6.1.1 Global Radiopharmaceuticals for Diagnosis Sales by Type (2020-2031) & (K Units)
- 6.1.2 Global Radiopharmaceuticals for Diagnosis Sales Market Share by Type (2020-2031)
- 6.2 Global Radiopharmaceuticals for Diagnosis Revenue by Type (2020-2031)
- 6.2.1 Global Radiopharmaceuticals for Diagnosis Sales by Type (2020-2031) & (US$ Million)
- 6.2.2 Global Radiopharmaceuticals for Diagnosis Revenue Market Share by Type (2020-2031)
- 6.3 Global Radiopharmaceuticals for Diagnosis Price by Type (2020-2031)
- 7 Segment by Application
- 7.1 Global Radiopharmaceuticals for Diagnosis Sales by Application (2020-2031)
- 7.1.1 Global Radiopharmaceuticals for Diagnosis Sales by Application (2020-2031) & (K Units)
- 7.1.2 Global Radiopharmaceuticals for Diagnosis Sales Market Share by Application (2020-2031)
- 7.2 Global Radiopharmaceuticals for Diagnosis Revenue by Application (2020-2031)
- 7.2.1 Global Radiopharmaceuticals for Diagnosis Sales by Application (2020-2031) & (US$ Million)
- 7.2.2 Global Radiopharmaceuticals for Diagnosis Revenue Market Share by Application (2020-2031)
- 7.3 Global Radiopharmaceuticals for Diagnosis Price by Application (2020-2031)
- 8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Radiopharmaceuticals for Diagnosis Value Chain Analysis
- 8.1.1 Radiopharmaceuticals for Diagnosis Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Radiopharmaceuticals for Diagnosis Production Mode & Process
- 8.2 Radiopharmaceuticals for Diagnosis Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Radiopharmaceuticals for Diagnosis Distributors
- 8.2.3 Radiopharmaceuticals for Diagnosis Customers
- 9 Global Radiopharmaceuticals for Diagnosis Analyzing Market Dynamics
- 9.1 Radiopharmaceuticals for Diagnosis Industry Trends
- 9.2 Radiopharmaceuticals for Diagnosis Industry Drivers
- 9.3 Radiopharmaceuticals for Diagnosis Industry Opportunities and Challenges
- 9.4 Radiopharmaceuticals for Diagnosis Industry Restraints
- 10 Report Conclusion
- 11 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.